Acquisition Context Circularis Biotechnologies was acquired by Ginkgo Bioworks in October 2022, signaling potential alignment with large-scale contract research, platform licensing, or integration opportunities for Circularis technologies within a larger biotech ecosystem.

Circular RNA Platform The company specializes in circular RNA to control gene expression across species and cell types, offering a scalable, high-throughput approach that could appeal to firms seeking versatile gene regulation tools for therapeutics, production optimization, and novel screening services.

Low Revenue, Big Upside Current revenue is under one million, indicating a growth-ready profile where strategic partnerships, licensing deals, or pilot programs with larger pharma or contract research organizations could unlock rapid revenue expansion and platform validation.

Targeted Market Fit Capabilities enable improved gene therapy targeting and expression in poorly studied organisms, presenting opportunities to partner with biotech companies focusing on niche biologics, rare disease programs, or non-traditional model systems that require bespoke gene regulation solutions.

Tech & IP Leverage Despite a small team, the platform’s high-throughput design and promoter screening potential can attract collaborations around platform integration, co-development, or exclusive licensing of circular RNA tools for clients with fast-paced development timelines.